+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Active Pharmaceutical Ingredients Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4851418
  • Report
  • November 2018
  • Region: Global
  • 190 pages
  • Transparency Market Research
1 of 2

Active Pharmaceutical Ingredients (API) Market - Overview

Biotech/biological APIs have witnessed constant technological evolution, owing to a shift from synthetic chemical APIs to biotech/biological APIs in the global active pharmaceutical ingredients market.

Rise in demand for new drugs at a low cost and entry of domestic and global companies in the APIs market have led to innovative product offerings with new and advanced techniques. Any substance or combination of substances used in a finished pharmaceutical product (FPP) is known as active pharmaceutical ingredients (API). A finished dose of any drug is a combination of active pharmaceutical ingredients and excipients. An excipient is an inactive substance in a drug dose.

High-potency active pharmaceutical ingredients (HPAPIs) and antibody-drug conjugates are recent innovations in the market and require a special manufacturing set up. Most of these drugs are used in oncology. A large number of patents for small molecule APIs are expected to expire in the next few years, with many drugs losing patent protection in 2018. This is estimates to unlock a significant market opportunity for generic drug manufacturers, resulting in augmented demand for APIs. Large pharmaceutical companies are scaling down their small molecule manufacturing facilities to focus on biologic drugs, thereby presenting greater opportunities for contract manufacturing companies, particularly in Asia.

A key trend of collaborations and acquisitions of related companies to increase geographic presence has been observed in the last few years. For instance, in July 2017, Sun Pharmaceutical Industries Ltd. entered into a long-term manufacturing agreement with Samsung BioLogics for the manufacture of Ilumya.

The global active pharmaceutical ingredients market has been broadly segmented based on manufacturer, APIs, drug, therapeutic, and region. In terms of manufacturer, the global market has been classified into in-house API manufacturing and API contract manufacturing. The in-house API manufacturing segment accounted for a key share of the global market, in terms of revenue, in 2017. The API contract manufacturing segment is estimated to expand at a significant growth rate during the forecast period. Consequently, the segment is estimated to gain significant market share by the end of 2026.

In terms of region, the global active pharmaceutical ingredients market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market and is projected to lose market share by the end of 2026. The market in North America is primarily driven by a rapid increase in the geriatric population, high adoption of new drugs, and rise in group dental practices in the U.S.. The market in Asia Pacific is projected to expand at a rapid pace during the forecast period. In Asia Pacific, Japan dominated the active pharmaceutical ingredients market, while the market in China is estimated to expand at a prominent CAGR during the forecast period. The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Major players operating in global active pharmaceutical ingredients market include Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Pfizer Inc., Boehringer Ingelheim International GmbH., Merck & Co., Inc., Novartis AG, F. Hoffmann-La Roche Ltd, and Bayer AG.

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Active Pharmaceutical Ingredients (API)

4. Market Overview
4.1. Introduction
4.1.1. Type of Manufacturers Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1. Increase in Abbreviated New Drug Applications (ANDA) in the Recent Past Boosted the Demand for APIs
4.3.1.2. Increasing Government Prioritization for Biomedical Innovation
4.3.1.3. Increase in Drug Master File (DMF) Filing from Indian and Chinese Companies Indicates a Rapid API market growth
4.3.1.4. Increasing Incidence of Acute and Chronic Diseases
4.3.1.5. Increasing Biopharmaceuticals Uptake Globally
4.3.2. Restraints
4.3.2.1.Strict European Union Regulatory Policies Restraining Market Growth
4.3.2.2. Unfavorable Drug Price Control Policies
4.3.3. Opportunities
4.3.4. Key Trends
4.3.4.1. Biologics Expected to be Key Pipeline Trend
4.3.4.2. Increase in Focus on Research & Development
4.3.4.3. Shift from Branded to Generics
4.3.4.4. Governments Encouraging Development of Orphan Drugs
4.4. Global Active Pharmaceutical Ingredients (API) Analysis and Forecasts, 2016-2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1. Value Chain Analysis
5.2. Patent Expiry of Major Drugs in 2018
5.3. Patent Expiry of Major Drugs in 2019 & 2020

6. Global Active Pharmaceutical Ingredients (API) Analysis and Forecasts, by Type of Manufacturers
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast by Type of Manufacturers, 2016-2026
6.3.1. In-house API Manufacturing
6.3.2. API Contract Manufacturing
6.4. Market Attractiveness, by Type of Manufacturers

7. Global Active Pharmaceutical Ingredients (API) Analysis and Forecasts, by Type of APIs
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Type of APIs, 2016-2026
7.3.1. Synthetic Chemical API
7.3.2. Biotech/Biological API
7.3.3. Plant Extracts API
7.3.4. High-potency API
7.3.5. Classical Fermentation API
7.4. Market Attractiveness, by Type of APIs

8. Global Active Pharmaceutical Ingredients (API) Analysis and Forecasts, by Type of Drug
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Type of Drug, 2016-2026
8.3.1. Branded or Innovative Prescription Drugs
8.3.2. Generic Prescription Drugs
8.3.3. Over-the-counter (OTC) Drugs
8.3.4. Others
8.4. Market Attractiveness, by Type of Drug

9. Global Active Pharmaceutical Ingredients (API) Analysis and Forecasts, by Therapeutic
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Therapeutic, 2016-2026
9.3.1. Anti-infective Drugs
9.3.2. Metabolic Disorders Drugs
9.3.3. Cardiovascular Drugs
9.3.4. Oncology Drugs
9.3.5. Central Nervous System Drugs
9.3.6. Respiratory Diseases Drugs
9.3.7. Others
9.4. Market Attractiveness, by Therapeutic

10. Global Active Pharmaceutical Ingredients (API) Analysis and Forecasts, by Region
10.1. Key Findings
10.2. Market Value Forecast by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region

11. North America Active Pharmaceutical Ingredients (API) Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2.Market Value Forecast, by Type of Manufacturers, 2016-2026
11.2.1. In-house API Manufacturing
11.2.2. API Contract Manufacturing
11.3.Market Value Forecast, by Type of APIs, 2016-2026
11.3.1. Synthetic Chemical API
11.3.2. Biotech/Biological API
11.3.3. Plant Extracts API
11.3.4. High-potency API
11.3.5. Classical Fermentation API
11.4.Market Value Forecast, by Type of Drug, 2016-2026
11.4.1. Branded or Innovative Prescription Drugs
11.4.2. Generic Prescription Drugs
11.4.3. over-the-counter (OTC) Drugs
11.4.4. Others
11.5.Market Value Forecast, by Therapeutic, 2016-2026
11.5.1. Anti-infective Drugs
11.5.2. Metabolic Disorders Drugs
11.5.3. Cardiovascular Drugs
11.5.4. Oncology Drugs
11.5.5. Central Nervous System Drugs
11.5.6. Respiratory Diseases Drugs
11.5.7. Others
11.6.Market Value Forecast, by Country, 2016-2026
11.6.1. U.S.
11.6.2. Canada
11.7.Market Attractiveness Analysis
11.7.1. By Type of Manufacturers
11.7.2. By Type of APIs
11.7.3. By Type of Drug
11.7.4. By Therapeutic
11.7.5. By Country

12. Europe Active Pharmaceutical Ingredients (API) Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2.Market Value Forecast, by Type of Manufacturers, 2016-2026
12.2.1. In-house API Manufacturing
12.2.2. API Contract Manufacturing
12.3.Market Value Forecast, by Type of APIs, 2016-2026
12.3.1. Synthetic Chemical API
12.3.2. Biotech/Biological API
12.3.3. Plant Extracts API
12.3.4. High-potency API
12.3.5. Classical Fermentation API
12.4.Market Value Forecast, by Type of Drug, 2016-2026
12.4.1. Branded or Innovative Prescription Drugs
12.4.2. Generic Prescription Drugs
12.4.3. Over-the-counter (OTC) Drugs
12.4.4. Others
12.5.Market Value Forecast, by Therapeutic, 2016-2026
12.5.1. Anti-infective Drugs
12.5.2. Metabolic Disorders Drugs
12.5.3. Cardiovascular Drugs
12.5.4. Oncology Drugs
12.5.5. Central Nervous System Drugs
12.5.6. Respiratory Diseases Drugs
12.5.7. Others
12.6.Market Value Forecast, by Country/Sub-region, 2016-2026
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7.Market Attractiveness Analysis
12.7.1. By Type of Manufacturers
12.7.2. By Type of APIs
12.7.3. By Type of Drug
12.7.4. By Therapeutic
12.7.5. By Country/Sub-region

13. Asia Pacific Active Pharmaceutical Ingredients (API) Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2.Market Value Forecast, by Type of Manufacturers, 2016-2026
13.2.1. In-house API Manufacturing
13.2.2. API Contract Manufacturing
13.3.Market Value Forecast, by Type of APIs, 2016-2026
13.3.1. Synthetic Chemical API
13.3.2. Biotech/Biological API
13.3.3. Plant Extracts API
13.3.4. High-potency API
13.3.5. Classical Fermentation API
13.4.Market Value Forecast, by Type of Drug, 2016-2026
13.4.1. Branded or Innovative Prescription Drugs
13.4.2. Generic Prescription Drugs
13.4.3. Over-the-counter (OTC) Drugs
13.4.4. Others
13.5.Market Value Forecast, by Therapeutic, 2016-2026
13.5.1. Anti-infective Drugs
13.5.2. Metabolic Disorders Drugs
13.5.3. Cardiovascular Drugs
13.5.4. Oncology Drugs
13.5.5. Central Nervous System Drugs
13.5.6. Respiratory Diseases Drugs
13.5.7. Others
13.6.Market Value Forecast, by Country/Sub-region, 2016-2026
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7.Market Attractiveness Analysis
13.7.1. By Type of Manufacturers
13.7.2. By Type of APIs
13.7.3. By Type of Drug
13.7.4. By Therapeutic
13.7.5. By Country/Sub-region

14. Latin America Active Pharmaceutical Ingredients (API) Analysis and Forecast
14.1.Introduction
14.1.1. Key Findings
14.2.Market Value Forecast, by Type of Manufacturers, 2016-2026
14.2.1. In-house API Manufacturing
14.2.2. API Contract Manufacturing
14.3.Market Value Forecast, by Type of APIs, 2016-2026
14.3.1. Synthetic Chemical API
14.3.2. Biotech/Biological API
14.3.3. Plant Extracts API
14.3.4. High-potency API
14.3.5. Classical Fermentation API
14.4.Market Value Forecast, by Type of Drug, 2016-2026
14.4.1. Branded or Innovative Prescription Drugs
14.4.2. Generic Prescription Drugs
14.4.3. Over-the-counter (OTC) Drugs
14.4.4. Others
14.5.Market Value Forecast, by Therapeutic, 2016-2026
14.5.1. Anti-infective Drugs
14.5.2. Metabolic Disorders Drugs
14.5.3. Cardiovascular Drugs
14.5.4. Oncology Drugs
14.5.5. Central Nervous System Drugs
14.5.6. Respiratory Diseases Drugs
14.5.7. Others
14.6.Market Value Forecast, by Country/Sub-region, 2016-2026
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7.Market Attractiveness Analysis
14.7.1. By Type of Manufacturers
14.7.2. By Type of APIs
14.7.3. By Type of Drug
14.7.4. By Therapeutic
14.7.5. By Country/Sub-region

15. Middle East & Africa Active Pharmaceutical Ingredients (API) Analysis and Forecast
15.1.Introduction
15.1.1. Key Findings
15.2.Market Value Forecast, by Type of Manufacturers, 2016-2026
15.2.1. In-house API Manufacturing
15.2.2. API Contract Manufacturing
15.3.Market Value Forecast, by Type of APIs, 2016-2026
15.3.1. Synthetic Chemical API
15.3.2. Biotech/Biological API
15.3.3. Plant Extracts API
15.3.4. High-potency API
15.3.5. Classical Fermentation API
15.4.Market Value Forecast, by Type of Drug, 2016-2026
15.4.1. Branded or Innovative Prescription Drugs
15.4.2. Generic Prescription Drugs
15.4.3. Over-the-counter (OTC) Drugs
15.4.4. Others
15.5.Market Value Forecast, by Therapeutic, 2016-2026
15.5.1. Anti-infective Drugs
15.5.2. Metabolic Disorders Drugs
15.5.3. Cardiovascular Drugs
15.5.4. Oncology Drugs
15.5.5. Central Nervous System Drugs
15.5.6. Respiratory Diseases Drugs
15.5.7. Others
15.6.Market Value Forecast, by Country/Sub-region, 2016-2026
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Israel
15.6.4. Rest of Middle East & Africa
15.7.Market Attractiveness Analysis
15.7.1. By Type of Manufacturers
15.7.2. By Type of APIs
15.7.3. By Type of Drug
15.7.4. By Therapeutic
15.7.5. By Country/Sub-region

16. Competition Landscape
16.1.Market Player - Competition Matrix (By Tier and Size of companies)
16.2.Market Share Analysis, by Company (2017)
16.5. Company Profiles
16.5.1. Teva Pharmaceutical Industries Ltd.
16.5.2. Sun Pharmaceutical Industries Ltd.
16.5.3. Aurobindo Pharma
16.5.4. Pfizer Inc.
16.5.5. Boehringer Ingelheim International GmbH.
16.5.6. Merck & Co., Inc.
16.5.7. Novartis AG
16.5.8. F. Hoffmann-La Roche Ltd
16.5.9. Bayer AG
16.5.10. Others
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll